Table 2.
Hazard ratios (green cell) of the network meta-analysis of the progression-free survival and overall survival.
| Progression-free survival | |||||
|---|---|---|---|---|---|
| Atec | Durc | Pemc | Nivc | Ipic | |
| Atec | 1 | 0.96 (95%CI: 0.72–1.3) | 1.0 (95%CI: 0.76–1.4) | 1.2 (95%CI: 0.79–1.8) | 0.91 (95%CI: 0.7–1.2) |
| Durc | 1.0 (95%CI: 0.78–1.4) | 1 | 1.1 (95%CI: 0.81–1.4) | 1.2 (95%CI: 0.83–1.8) | 0.94 (95%CI: 0.75–1.2) |
| Pemc | 0.97 (95%CI: 0.72–1.3) | 0.94 (95%CI: 0.71–1.2) | 1 | 1.2 (95%CI: 0.78–1.7) | 0.88 (95%CI: 0.7–1.1) |
| Nivc | 0.84 (95%CI: 0.56–1.3) | 0.81 (95%CI: 0.55–1.2) | 0.87 (95%CI: 0.58–1.3) | 1 | 0.77 (95%CI: 0.53–1.1) |
| Ipic | 1.1 (95%CI: 0.86–1.4) | 1.1 (95%CI: 0.85–1.3) | 1.1 (95%CI: 0.89–1.4) | 1.3 (95%CI: 0.91–1.9) | 1 |
| Overall survival | |||||
| Atec | Durc | Pemc | Nivc | Ipic | |
| Atec | 1 | 0.93 (95%CI: 0.67–1.3) | 0.87 (95%CI: 0.62–1.2) | 1.0 (95%CI: 0.66–1.7) | 0.74 (95%CI: 0.55–1.0) |
| Durc | 1.1 (95%CI: 0.77–1.5) | 1 | 0.94 (95%CI: 0.71–1.3) | 1.1 (95%CI: 0.73–1.7) | 0.8 (95%CI: 0.63–1.0) |
| Pemc | 1.1 (95%CI: 0.81–1.6) | 1.1 (95%CI: 0.8–1.4) | 1 | 1.2 (95%CI: 0.77–1.8) | 0.85 (95%CI: 0.66–1.1) |
| Nivc | 0.96 (95%CI: 0.6–1.5) | 0.89 (95%CI: 0.58–1.4) | 0.84 (95%CI: 0.54–1.3) | 1 | 0.71 (95%CI: 0.47–1.1) |
| Ipic | 1.3 (95%CI: 0.99–1.8) | 1.3 (95%CI: 0.98–1.6) | 1.2 (95%CI: 0.91–1.5) | 1.4 (95%CI: 0.94–2.1) | 1 |
Atec, atezolizumab plus chemotherapy; Durc, durvalumab plus chemotherapy; Pemc, pembrolizumab plus chemotherapy; Nivc, nivolumab plus chemotherapy; Ipic, ipilimumab plus chemotherapy.